🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06586528
Recruiting Not applicable

Increasing Family Engagement in Critical Care

NCT06586528 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-03-26
Last updated
2025-05-18

Condition(s) studied

Family EngagementCritical Care, Intensive CarePatient and Family EngagementHealth Care DeliveryFamily-centered Care

Investigational drug(s) / intervention(s)

NGAGE tool

NGAGE tool: Access to NGAGE tool

Study summary

The primary aim of this trial is to evaluate if the NGAGE tool improves care engagement in family members of ICU patients. The secondary objectives are to assess if the NGAGE tool improves communication, care satisfaction, psychological symptoms, and quality of life in family members of ICU patients.

The NGAGE trial is a stepped wedge cluster randomized trial of 6 Canadian adult ICUs, involving 194 family members. A family member will be considered anyone with a biological, emotional, or legal relationship with the patient and whom the patient wishes to be involved in their care. There will be random and sequential crossover of clusters from control (phase 1) to intervention (phase 2) until all clusters are exposed. The intervention group will have access to the NGAGE tool, which has modules to Learn, Engage, and Report. "Engage" allows the family member to indicate their desired engagement activity, which is then transmitted to the treating healthcare team to provide the requested activity. "Learn" contains educational capsules about the ICU environment and information about care participation. "Report" allows the family member to provide real-time feedback to the healthcare team. The primary endpoint is the FAMily Engagement (FAME) score within 1 week of ICU discharge. Secondary endpoints are family-centered outcomes, including communication quality, satisfaction, and mental health (anxiety and depression) scores within 1 week of ICU discharge, and quality of life and mental health (anxiety, depression, and post-traumatic distress symptoms) at 6 months. The mean difference of the validated FAME score, a continuous variable, will be compared between groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult family members (age ≥ 18 years) of ICU patients * Expected ICU stay ≥ 48 hours * Able to participate in English or French Exclusion Criteria: * Family members who do not wish to participate in care * Repeat admissions within the study period * Another family member has already participated in the study

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Jewish General Hospital Montreal Quebec Recruiting
McGill University Health Centre Montreal Quebec Recruiting

More Lady Davis Institute trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06586528 on ClinicalTrials.gov ↗ ← All trials in Canada